Literature DB >> 25604237

Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND).

Zaina Zayyad1, Serena Spudich.   

Abstract

Early in the HIV epidemic, the central nervous system (CNS) was recognized as a target of infection and injury in the advanced stages of disease. Though the most severe forms of HIV-associated neurocognitive disorder (HAND) related to severe immunosuppression are rare in the current era of widespread combination antiretroviral therapy (cART), evidence now supports pathological involvement of the CNS throughout the course of infection. Recent work suggests that the stage for HIV neuropathogenesis may be set with initial viral entry into the CNS, followed by initiation of pathogenetic processes including neuroinflammation and neurotoxicity, and establishment of local, compartmentalized HIV replication that may reflect a tissue reservoir for HIV. Key questions still exist as to when HIV establishes local infection in the CNS, which CNS cells are the primary targets of HIV, and what mechanistic processes underlie the injury to neurons that produce clinical symptoms of HAND. Advances in these areas will provide opportunities for improved treatment of patients with established HAND, prevention of neurological disease in those with early stage infection, and understanding of HIV tissue reservoirs that will aid efforts at HIV eradication.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25604237      PMCID: PMC4741099          DOI: 10.1007/s11904-014-0255-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  83 in total

1.  Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.

Authors:  A H Shin; H J Kim; S A Thayer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Acute ataxia coincident with seroconversion for anti-HIV.

Authors:  E Scarpini; G Sacilotto; A Lazzarin; L Geremia; R Doronzo; G Scarlato
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

Review 3.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

4.  Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

Authors:  Meagan O'Brien; Emilie Montenont; Liang Hu; Michael A Nardi; Vanessa Valdes; Michael Merolla; Gabrielle Gettenberg; Karen Cavanagh; Judith A Aberg; Nina Bhardwaj; Jeffrey S Berger
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

5.  Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model.

Authors:  Sheila A Barber; Lucio Gama; Justyna M Dudaronek; Tauni Voelker; Patrick M Tarwater; Janice E Clements
Journal:  J Infect Dis       Date:  2006-02-21       Impact factor: 5.226

6.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

7.  Neonatal intrahippocampal HIV-1 protein Tat(1-86) injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation.

Authors:  Landhing M Moran; Sylvia Fitting; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2014-10-05       Impact factor: 2.457

8.  Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.

Authors:  Kelly A Meulendyke; Suzanne E Queen; Elizabeth L Engle; Erin N Shirk; Jiayang Liu; Joseph P Steiner; Avindra Nath; Patrick M Tarwater; David R Graham; Joseph L Mankowski; M Christine Zink
Journal:  J Neurovirol       Date:  2014-09-17       Impact factor: 2.643

9.  Differential effects of Tat proteins derived from HIV-1 subtypes B and recombinant CRF02_AG on human brain microvascular endothelial cells: implications for blood-brain barrier dysfunction.

Authors:  Shawna M Woollard; Biju Bhargavan; Fang Yu; Georgette D Kanmogne
Journal:  J Cereb Blood Flow Metab       Date:  2014-03-26       Impact factor: 6.200

10.  Dopamine receptor activation increases HIV entry into primary human macrophages.

Authors:  Peter J Gaskill; Hideaki H Yano; Ganjam V Kalpana; Jonathan A Javitch; Joan W Berman
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

View more
  79 in total

1.  Soluble membrane attack complex in the blood and cerebrospinal fluid of HIV-infected individuals, relationship to HIV RNA, and comparison with HIV negatives.

Authors:  Albert M Anderson; Theresa N Schein; Aley Kalapila; Lillin Lai; Drenna Waldrop-Valverde; Raeanne C Moore; Donald Franklin; Scott L Letendre; Scott R Barnum
Journal:  J Neuroimmunol       Date:  2017-07-23       Impact factor: 3.478

Review 2.  CROI 2016: Neurologic Complications of HIV Infection.

Authors:  Serena S Spudich; Beau M Ances
Journal:  Top Antivir Med       Date:  2016 May-Jun

Review 3.  Neuroimaging the Neuropathogenesis of HIV.

Authors:  Anna H Boerwinkle; Karin L Meeker; Patrick Luckett; Beau M Ances
Journal:  Curr HIV/AIDS Rep       Date:  2021-02-25       Impact factor: 5.071

Review 4.  Childhood maltreatment and HIV-associated neurocognitive disorders share similar pathophysiology: a potential sensitisation mechanism?

Authors:  Jacqueline S Womersley; Soraya Seedat; Sian M J Hemmings
Journal:  Metab Brain Dis       Date:  2017-07-05       Impact factor: 3.584

5.  Chronic Kidney Disease in the Aging Human Immunodeficiency Virus-Infected Population.

Authors:  Jeffrey B Kopp
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

6.  Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.

Authors:  Josué Pérez-Santiago; Michelli F De Oliveira; Susanna R Var; Tyler R C Day; Steven P Woods; Sara Gianella; Sanjay R Mehta
Journal:  J Neurovirol       Date:  2016-12-05       Impact factor: 2.643

7.  Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.

Authors:  Michael J Peluso; Victor Valcour; Nittaya Phanuphak; Jintanat Ananworanich; James L K Fletcher; Thep Chalermchai; Shelly J Krebs; Merlin L Robb; Joanna Hellmuth; Magnus Gisslén; Henrik Zetterberg; Serena Spudich
Journal:  AIDS       Date:  2017-01-14       Impact factor: 4.177

Review 8.  HIV, opiates, and enteric neuron dysfunction.

Authors:  J J Galligan
Journal:  Neurogastroenterol Motil       Date:  2015-04       Impact factor: 3.598

9.  Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.

Authors:  Kevin Robertson; Alan Landay; Sachiko Miyahara; Alyssa Vecchio; Mary Clare Masters; Todd T Brown; Babafemi O Taiwo
Journal:  J Neurovirol       Date:  2019-08-29       Impact factor: 2.643

Review 10.  Treating HIV Infection in the Central Nervous System.

Authors:  A Calcagno; G Di Perri; S Bonora
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.